Search results
Showing 1126 to 1140 of 1877 results for do not dos
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)
NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant (HTG732)
Evidence-based recommendations on direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. This involves inserting a metal implant through the skin and into the centre of the bone of the stump and attaching a prosthetic limb to it.
View recommendations for HTG732Show all sections
Medicines management for people receiving social care in the community (QS171)
This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.
View quality statements for QS171Show all sections
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)
Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.
Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.
How you can use our recommendations, tools and resources: maternity and neonatal health
How to use NICE guidance to reduce health inequalities during and after pregnancy.
How you can use our recommendations, tools and resources: cardiovascular disease
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social value issues.
Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.